Redirecting to original paper in 30 seconds...
Click below to go immediately or wait for automatic redirect
📄 Abstract
Abstract: Drug synergy prediction is a critical task in the development of effective
combination therapies for complex diseases, including cancer. Although existing
methods have shown promising results, they often operate as black-box
predictors that rely predominantly on statistical correlations between drug
characteristics and results. To address this limitation, we propose CausalDDS,
a novel framework that disentangles drug molecules into causal and spurious
substructures, utilizing the causal substructure representations for predicting
drug synergy. By focusing on causal sub-structures, CausalDDS effectively
mitigates the impact of redundant features introduced by spurious
substructures, enhancing the accuracy and interpretability of the model. In
addition, CausalDDS employs a conditional intervention mechanism, where
interventions are conditioned on paired molecular structures, and introduces a
novel optimization objective guided by the principles of sufficiency and
independence. Extensive experiments demonstrate that our method outperforms
baseline models, particularly in cold start and out-of-distribution settings.
Besides, CausalDDS effectively identifies key substructures underlying drug
synergy, providing clear insights into how drug combinations work at the
molecular level. These results underscore the potential of CausalDDS as a
practical tool for predicting drug synergy and facilitating drug discovery.
Key Contributions
CausalDDS is a novel framework for drug synergy prediction that disentangles drug molecules into causal and spurious substructures. By focusing on causal representations and employing a conditional intervention mechanism with a novel optimization objective, it enhances accuracy, interpretability, and generalizability.
Business Value
Accelerates the discovery of effective combination therapies by providing more reliable and interpretable predictions, reducing R&D costs and time in drug development.